Bioventus Inc. (NYSE:BVS) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in Bioventus Inc. (NYSE:BVS) by 38.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 390,162 shares of the company’s stock after purchasing an additional 109,359 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.48% of Bioventus worth $4,662,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Intech Investment Management LLC purchased a new stake in Bioventus in the 3rd quarter worth about $167,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Bioventus in the 3rd quarter worth about $3,092,000. Segall Bryant & Hamill LLC acquired a new position in Bioventus in the 3rd quarter worth about $4,515,000. Quest Partners LLC acquired a new position in Bioventus in the 3rd quarter worth about $51,000. Finally, Royce & Associates LP acquired a new position in Bioventus in the 3rd quarter worth about $8,337,000. Institutional investors own 62.94% of the company’s stock.

Bioventus Stock Performance

BVS opened at $11.03 on Friday. The firm has a market capitalization of $895.08 million, a P/E ratio of -18.08 and a beta of 0.79. The stock’s 50 day moving average price is $12.08 and its two-hundred day moving average price is $9.52. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a 12-month low of $3.90 and a 12-month high of $14.38.

Bioventus (NYSE:BVS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The company had revenue of $138.96 million during the quarter, compared to the consensus estimate of $132.57 million. During the same quarter last year, the company earned $0.05 EPS. On average, equities analysts forecast that Bioventus Inc. will post 0.41 earnings per share for the current year.

Analyst Ratings Changes

BVS has been the topic of a number of analyst reports. Canaccord Genuity Group increased their price objective on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Craig Hallum increased their price objective on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.